Soleus Capital Acquires 5.8% Stake in Processa Pharmaceuticals

On August 18, 2026, Soleus Capital Master Fund, L.P., along with its affiliates and managing member Guy Levy, filed a Schedule 13G regarding their holdings in Processa Pharmaceuticals, Inc. (PCSA). The filing reveals that as of August 3, 2026, the reporting persons collectively acquired 160,943 shares of common stock, representing a 5.8% ownership stake in the company. This acquisition marks a new significant position for the investment group, as the previous reported ownership was zero. The shares are held directly by the Master Fund, with Soleus Capital, LLC acting as the general partner and Soleus Capital Management, L.P. serving as the investment manager. Guy Levy, the managing member of the involved entities, shares voting and dispositive power over the shares. The filing was made under Rule 13d-1(c), indicating a passive investment intent without the purpose of influencing or changing the control of the issuer. The calculation of the ownership percentage is based on 2,793,386 shares outstanding as of August 7, 2026.